Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

European Commission Approval of Tucatinib in HER2+ BC

April 7th 2021

Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.

Dr. Meisel on Managing Toxicities Associated with T-DM1 in HER2+ Breast Cancer

April 6th 2021

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Bhave Spotlights Breakthroughs Made With Immunotherapy Combinations in TNBC

April 6th 2021

Chemoimmunotherapy has become the standard of care for the frontline treatment of patients with PD-L1–positive, locally advanced or metastatic triple-negative breast cancer. However, understanding which patients will derive the most benefit from the approach is in need of further exploration

Longer Follow-Up Is Imperative With Adjuvant CDK4/6 Inhibitors in ER+ Breast Cancer

April 5th 2021

Optimal patient selection and duration of therapy are the 2 biggest areas to tackle regarding CDK4/6 inhibition in the adjuvant setting of estrogen receptor–positive breast cancer.

Experts Take a Fresh Look at Strategies for Early-Stage HER2+ Breast Cancer

April 5th 2021

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer

April 3rd 2021

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.

A New Crop of ER-Targeting Agents Takes Root

April 2nd 2021

Although endocrine therapies have revolutionized the treatment of breast cancers driven by the estrogen receptor, the development of resistance remains a major challenge that limits long-term remission with currently available drugs.

The Marshalls Open a Candid Conversation About Cancer

April 1st 2021

The Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Approval Sought for Plinabulin Plus G-CSF in United States and China for Prevention of CIN

April 1st 2021

A new drug application has been submitted to the FDA and the China National Medical Products Administration for the use of plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

FDA Approval Sought for F-627 for Chemotherapy-Induced Neutropenia in Breast Cancer

March 31st 2021

A biologics license application has been submitted to the FDA for the approval of F-627 as a treatment option for patients with breast cancer who have chemotherapy-induced neutropenia.

Dr. Kalinsky on the Potential Role of Ovarian Function Suppression in HR+/HER2- Breast Cancer

March 30th 2021

Kevin Kalinsky, MD, MS, discusses the potential role of ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Applying RxPONDER to Clinical Practice

March 30th 2021

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

Dr. White on Research With Regional Nodal Irradiation in Node-Positive Breast Cancer

March 29th 2021

Julia R. White, MD, discusses research with regional nodal irradiation in node-positive breast cancer.

FDA Issues Complete Response Letter for Neoadjuvant Pembrolizumab for High-Risk TNBC

March 29th 2021

The FDA has issued a complete response letter to Merck stating that regulatory decision for the supplemental biologics license application seeking approval for pembrolizumab for use in patients with high-risk, early-stage triple-negative breast cancer plus chemotherapy as neoadjuvant treatment, then continuing as a single agent as adjuvant treatment following surgery, should be deferred.

Sacituzumab Govitecan Application for Metastatic TNBC Fast-Tracked in Europe

March 26th 2021

The European Medicines Agency has validated a Marketing Authorization application for sacituzumab govitecan-hziy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who had previously received at least 2 therapies, including at least 1 therapy for locally advanced or metastatic disease.

First-Line Palbociclib/Letrozole Shows Real-World Survival Benefit in HR+ Metastatic Breast Cancer

March 25th 2021

Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting.

Clinical Factors Drive Choice of CDK4/6 Inhibitors for Hormone Receptor–Positive Breast Cancer

March 25th 2021

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.

FDA Grants 2 Breakthrough Device Designations to Signatera MRD Test

March 24th 2021

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Dr. Borgen on Common Symptoms of Male Breast Cancer

March 24th 2021

Patrick Borgen, MD, discusses common symptoms of breast cancer in male patients.